Shared care guidelines for paediatric use of daily and long-acting recombinant human growth hormone

Shared care guidelines for paediatric use of daily and long-acting recombinant human growth hormone - British Society for Paediatric Endocrinology and Diabetes (BSPED)

The BSPED growth hormone therapy shared care guidelines were produced by the BSPED Clinical Committee in August 2015. These guidelines were updated by the BSPED Growth Disorders Special Interest Group (SIG) in December 2023.

Recombinant human GH (r-hGH) is available as a daily (somatropin) or as long-acting growth hormone (LAGH) preparations. Currently somatrogon is the only LAGH preparation available but other LAGH preparations are likely to be licenced.


Read full Guideline